Baxter International Inc.

Baxter Healthcare Sa

Baxalta Gmbh

Abivax

Takeda Pharmaceutical Company Limited

Ology Bioservices Inc.

Other

Hartmut Ehrlich

Friedrich Scheiflinger

Michael Dockal

Hans-Peter Schwarz

Birgit Maria Reipert

Ulrich Reineke

Thomas Polakowski

Frank Osterkamp

Rudolf Hartmann

Markus Fries

Didier Scherrer

Eberhard Schneider

Ulf Reimer

Philippe Pouletty

Patrick Küry

Hans-Peter Hartung

Nevena Tzekova

Corinna Hermann

Sebastian Bunk

Sandrine Crabe

Thomas R Kreil

Falko-Günter Falkner

P Noel Barrett

Birgit Schafer

Annett Hessel

Katharina Nora Steinitz

Paula Maria Wilhelmina Van Helden

Juergen Siekmann

Noel Barrett

Falko-Guenter Falkner

Otfried Kistner

Gerhard Antoine

Christian Lubich

Maria Sasgary

Maria Schuster

Katarzyna Olas

Irina Elovaara

Birgit Schäfer

Patrick Kuery

Birgit Reipert

An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.

Combinations including ABX196 for the treatment of cancer

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.

TFPI inhibitors and methods of use

The compound ABX196 and pharmaceutical compositions including ABX196 are used in the treatment of bladder cancer.

ABX196 for use in the treatment of bladder cancer

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.

IgG stimulated remyelination of peripheral nerves

The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses.

Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses

The present invention relates, in general, to materials and methods for production of an improved vaccine against influenza virus, wherein the vaccine comprises a reassortant virus having a hemagglutinin gene and a neuraminidase gene from the same influenza A virus subtype or influenza B strain of virus and internal genes from a different influenza A virus subtype or influenza B strain of virus. In one aspect, the HA and NA genes and the internal genes are from a highly pathogenic H5N1 strain of influenza A.

Production of viral vaccine

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.

The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.

FVIII peptides for immune tolerance induction and immunodiagnostics

Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.

Methods and compositions for treating bleeding disorders

Growing community of inventors

Vienna, Austria

Hartmut Ehrlich